Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 5/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14926166 | 0.71 | PDE10A (0.37) | HTT | |
| SCHEMBL24375398 | 0.70 | KAT2B (0.39) | KAT2B | |
| SCHEMBL26906263 | 0.64 | PHGDH (0.48) | — | |
| SCHEMBL19209835 | 0.63 | — | — | |
| SCHEMBL21238657 | 0.62 | KAT2B (0.42) | KAT2B | |
| SCHEMBL15740517 | 0.61 | UHRF1 (0.35) | KAT2BHTTAOC3 | |
| SCHEMBL24607763 | 0.61 | AOC1 (0.34) | KAT2BHTTAOC3 | |
| SCHEMBL19015055 | 0.61 | LMNA (0.33) | KAT2BHTTAOC3 | |
| SCHEMBL20519442 | 0.61 | RECQL (0.34) | — | |
| SCHEMBL29844749 | 0.61 | RECQL (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124604-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110105479-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105479-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | KAT2B 3871/4885HTT 4575/4885FGFR1 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.